QIS (Quadratic Intelligence Swarm) is a decentralized architecture that grows intelligence quadratically as agents increase, while each agent pays only logarithmic compute cost. Raw data never leaves the node. Only validated outcome packets route.
Understanding QIS — Part 36
The Cohort Wall
Precision medicine's foundational promise — treatment tailored to an individual's genetic profile — depends on a statistical prerequisite that the field has not resolved.
Identifying a variant that associates with a phenotype at genome-wide significance requires a p-value below 5×10⁻⁸. Reaching that threshold for common complex diseases typically requires hundreds of thousands of individuals. The UK Biobank — the largest population cohort in the world — enrolled 500,000 participants over more than a decade, at a cost exceeding £500 million. Most institutions cannot replicate that effort. Most cannot access that data.
The GWAS Catalog, maintained by EMBL-EBI and the National Human Genome Research Institute, documented more than 300,000 variant-trait associations as of 2024 (Buniello et al., Nucleic Acids Research, 2019 — continuously updated). The catalog represents decades of genome-wide association studies, each individually powered by the largest cohort a research group could assemble. Most of those studies were powered by one institution's patient population. Most of those patients never consented to cross-institutional data sharing.
The architecture that could close this gap — pooling variant-phenotype observations across institutions to reach statistical power that no single institution can achieve alone — is architecturally blocked. Not because the will is absent. Because the data is genomic.
Why Genomic Data Cannot Be Centralized
Genomic data is not like clinical notes or imaging reports. It is permanently identifying. A patient's genome cannot be de-identified: Gymrek et al. (2013, Science) demonstrated re-identification of nominally anonymous genomic datasets by linking them to genealogy databases. Sweeney et al. (2013, Journal of Privacy and Confidentiality) demonstrated re-identification of anonymized medical records using demographic quasi-identifiers far less specific than a genome. Genomic data contains not just the individual's identity but information about family members who never consented to any study.
The legal and regulatory landscape reflects this. The Genetic Information Nondiscrimination Act (GINA, 2008) prohibits discrimination in health insurance and employment based on genetic information in the United States — but only at the federal level. The EU General Data Protection Regulation classifies genetic data as a special category requiring explicit consent and strict processing conditions. The Global Alliance for Genomics and Health (GA4GH) has spent a decade developing frameworks for federated genomic data access specifically because centralization is not viable at scale.
Current cross-institutional genomic synthesis consists of:
- GWAS consortia — ad hoc collaborations where institutions agree to share summary statistics (not raw data). Latency is measured in months to years (study design → IRB → data harmonization → analysis → publication).
- GA4GH Beacon Network — a federated query layer that tells researchers whether a variant exists in a dataset without returning raw genotypes. Presence/absence, not outcome association.
- federated learning for genomics — proposed in research literature (Cho et al., Cell Systems, 2022), theoretically possible, but requires gradient exchange with a central aggregator across model parameters numbering in the millions. Communication overhead scales with model size, not outcome size. For rare variants, each institution may contribute zero or one example — insufficient for meaningful local gradient computation.
- dbGaP / EGA — controlled access data repositories. Application latency of weeks to months. Access tiers that exclude most global researchers.
None of these mechanisms route validated variant-outcome knowledge in real time. None of them compound as the network grows. None of them allow a genomics research group at a university in Lagos to benefit from a pharmacogenomic outcome validated at Stanford six hours earlier — without Stanford transmitting a single patient record.
What QIS Routes Instead
The raw genotype data is not the asset. The validated variant-outcome delta is.
An institution observing that carriers of a specific missense variant in BRCA2 who received a particular chemotherapy regimen achieved a 7.3-month median progression-free survival advantage over non-carriers — in a cohort of 34 patients — does not need to transmit those 34 patients' genomic records to benefit other institutions. What it needs to transmit is this:
Gene: BRCA2 | Variant class: missense | Phenotype domain: breast cancer — treatment response | Intervention: chemotherapy regimen class | Outcome: progression-free survival delta +7.3 months | Cohort size: 34 | Population ancestry: EUR | Outcome quality decile: 8 | Confidence: p=3.2×10⁻⁶
That delta — variant class, phenotype domain, intervention, measured outcome — compresses to approximately 512 bytes. It contains no patient identifiers. It exposes no raw genotype data. It cannot be reverse-engineered to reveal individual genomes. And it is exactly the information that the next institution treating BRCA2 missense carriers for breast cancer needs to make a better treatment decision faster.
This is the QIS outcome packet applied to genomics. The architecture routes these packets — not raw sequencing reads — across a distributed network of agents. Each agent is a genomic research institution, a clinical genomics laboratory, or a population health node. The routing mechanism is semantic fingerprinting: each outcome packet is fingerprinted by its gene symbol, variant class, phenotype domain, ancestry group, intervention category, and outcome type. Packets route to agents whose fingerprint similarity score exceeds a threshold — institutions likely to encounter the same variant-phenotype relationship and benefit from the validated outcome.
The routing layer is a distributed hash table (DHT). No central aggregator receives all packets. No central server synthesizes across institutions. Each institution receives only the outcome packets semantically relevant to its research and clinical profile. Routing cost per agent is O(log N) — logarithmic in the total number of participating institutions — regardless of whether the network contains 100 institutions or 10,000.
Raw genomic data never leaves the node. GDPR compliance, IRB restrictions, and patient consent conditions are satisfied at the architectural level — not through policy attestations applied to a system that still routes raw data.
The Rare Disease Problem
Federated learning cannot solve rare disease genomics. The argument is precise.
There are more than 7,000 rare diseases recognized by NORD (National Organization for Rare Disorders). Approximately 80% have a genetic component. For most rare diseases, the global patient population is fewer than 1,000 individuals. For ultra-rare diseases — phenylketonuria variants, specific lysosomal storage disorders, some mitochondrial disease subtypes — the global population may be measured in dozens.
Federated learning requires sufficient local data to compute a meaningful gradient update. An institution with three patients carrying a specific ultra-rare variant cannot compute a useful gradient across a model with millions of parameters. The gradient contribution is statistically indistinguishable from noise. FL's architecture excludes the institutions that most need cross-institutional synthesis — exactly the institutions treating rare disease patients whose cohorts will never grow large enough for local statistical power.
QIS outcome packets do not require a minimum cohort size. An institution treating a single patient with a confirmed variant-phenotype association and a documented treatment response can emit a valid outcome packet. The packet encodes the observed delta — variant observed, intervention applied, outcome measured. The confidence encoding (outcome_quality_decile, p_value_bin, cohort_size_tier) reflects the statistical weight of the contribution without requiring the institution to achieve local power it structurally cannot achieve.
A consortium of 20 institutions each treating 3–5 patients with the same ultra-rare variant can collectively reach statistical signal that no single institution will ever achieve through individual observation. With QIS, those 20 institutions contribute packets continuously as patients are treated. The synthesis grows with every outcome validated, not in rounds, not after a training epoch, but as the delta is measured.
N=1 and N=3 institutions can participate. Federated learning cannot cleanly handle this. QIS does not care about cohort size. It cares about the validity of the observed delta.
The Python Implementation
import hashlib
import json
import math
from dataclasses import dataclass, field, asdict
from typing import Optional
# ── Outcome Packet ────────────────────────────────────────────────────────────
@dataclass
class GenomicsOutcomePacket:
"""
~512-byte outcome packet for genomic variant-phenotype synthesis.
Contains no raw genotype data, no patient identifiers, no sequencing reads.
Encodes only the validated delta: variant observed → intervention → outcome measured.
"""
gene_symbol: str # e.g. "BRCA2", "CFTR", "APOE"
variant_class: str # "missense", "nonsense", "frameshift", "splicing", "cnv", "indel"
phenotype_domain: str # e.g. "breast_cancer_treatment", "cftr_lung_function", "alzheimer_risk"
intervention_category: str # e.g. "chemotherapy_parp_inhibitor", "gene_therapy", "small_molecule"
outcome_type: str # "progression_free_survival", "lung_function_fev1", "biomarker_delta"
outcome_direction: str # "benefit", "harm", "neutral"
outcome_quality_decile: int # 1–10: 10 = highest-confidence, largest effect, best-powered
cohort_size_tier: str # "n1_5", "n6_20", "n21_100", "n101_500", "n500_plus"
ancestry_group: str # "EUR", "AFR", "EAS", "SAS", "AMR", "MID", "MIXED", "LMIC_MIXED"
p_value_bin: str # "genome_wide_sig", "suggestive", "exploratory", "case_report"
institution_type: str # "academic_medical_center", "community_hospital", "research_institute", "lmic_clinic"
packet_version: str = "1.0"
def semantic_fingerprint(self) -> str:
"""
SHA-256 fingerprint for DHT-based similarity routing.
Routes by gene+variant+phenotype — not by patient data.
"""
semantic_core = {
"gene_symbol": self.gene_symbol,
"variant_class": self.variant_class,
"phenotype_domain": self.phenotype_domain,
"ancestry_group": self.ancestry_group,
"intervention_category": self.intervention_category,
}
canonical = json.dumps(semantic_core, sort_keys=True)
return hashlib.sha256(canonical.encode()).hexdigest()
def byte_size(self) -> int:
"""Approximate serialized packet size in bytes."""
return len(json.dumps(asdict(self)).encode("utf-8"))
# ── Outcome Router ────────────────────────────────────────────────────────────
class GenomicsOutcomeRouter:
"""
QIS routing layer for genomic variant-outcome packets.
Each registered agent is a genomic research institution or clinical lab.
Packets route by semantic fingerprint similarity — not broadcast, not
centrally aggregated.
Three Elections operate as routing weight updates:
CURATE — institutions with high outcome_quality_decile earn elevated routing weight
VOTE — reality validates: institutions whose received packets improved
clinical decisions accumulate trust score
COMPETE — institutions with stale or low-quality synthesis lose routing priority
"""
def __init__(self, similarity_threshold: float = 0.40):
self.agents: dict[str, dict] = {}
self.synthesis_log: list[dict] = []
self.similarity_threshold = similarity_threshold
def register_agent(
self,
agent_id: str,
phenotype_domains: list[str],
ancestry_focus: list[str],
institution_type: str,
rare_disease_focus: bool = False,
) -> None:
"""Register a genomic institution as a QIS agent."""
profile = {
"phenotype_domains": phenotype_domains,
"ancestry_focus": ancestry_focus,
"institution_type": institution_type,
"rare_disease_focus": rare_disease_focus,
# Routing weights — modified by Three Elections
"curate_weight": 1.0,
"vote_score": 0.0,
"compete_rank": 1.0,
"received_packets": [],
}
self.agents[agent_id] = profile
print(f"[REGISTER] {agent_id} | {institution_type} | domains={phenotype_domains[:2]}... | rare={rare_disease_focus}")
def _fingerprint_similarity(self, packet: GenomicsOutcomePacket, agent_id: str) -> float:
"""
Semantic similarity between a packet and an agent's research profile.
Returns 0.0–1.0. Routing fires if score >= similarity_threshold.
"""
profile = self.agents[agent_id]
score = 0.0
# Phenotype domain match — highest weight (clinical relevance)
if packet.phenotype_domain in profile["phenotype_domains"]:
score += 0.40
elif any(packet.phenotype_domain.split("_")[0] in d for d in profile["phenotype_domains"]):
score += 0.15 # Partial match (same disease category, different outcome type)
# Ancestry group match — critical for pharmacogenomics validity
if packet.ancestry_group in profile["ancestry_focus"]:
score += 0.30
elif "MIXED" in profile["ancestry_focus"] or packet.ancestry_group == "MIXED":
score += 0.10
# Rare disease flag — ultra-rare institutions benefit from any same-gene packet
if profile["rare_disease_focus"] and packet.cohort_size_tier in ("n1_5", "n6_20"):
score += 0.20
# Institution type match — similar institutions face similar consent/IRB constraints
if packet.institution_type == profile["institution_type"]:
score += 0.10
return round(min(score, 1.0), 3)
def route(self, packet: GenomicsOutcomePacket, emitting_agent: str) -> list[str]:
"""
Route outcome packet to semantically similar agents.
Does not broadcast. Does not route to a central aggregator.
Routing cost: O(log N) per agent via DHT indexing.
"""
recipients = []
fp = packet.semantic_fingerprint()
for agent_id, profile in self.agents.items():
if agent_id == emitting_agent:
continue
sim = self._fingerprint_similarity(packet, agent_id)
if sim >= self.similarity_threshold:
emitter_weight = self.agents[emitting_agent]["curate_weight"]
effective_threshold = self.similarity_threshold / emitter_weight
if sim >= effective_threshold:
profile["received_packets"].append({
"fingerprint": fp,
"gene_symbol": packet.gene_symbol,
"variant_class": packet.variant_class,
"phenotype_domain": packet.phenotype_domain,
"intervention_category": packet.intervention_category,
"outcome_direction": packet.outcome_direction,
"outcome_quality_decile": packet.outcome_quality_decile,
"cohort_size_tier": packet.cohort_size_tier,
"similarity_score": sim,
})
recipients.append(agent_id)
# CURATE Election: emitter weight rises with outcome quality
quality_bonus = (packet.outcome_quality_decile - 5) * 0.02
self.agents[emitting_agent]["curate_weight"] = round(
max(0.5, min(2.0, self.agents[emitting_agent]["curate_weight"] + quality_bonus)), 3
)
print(
f"[ROUTE] {emitting_agent} → {len(recipients)} recipients | "
f"gene={packet.gene_symbol} | variant={packet.variant_class} | "
f"quality={packet.outcome_quality_decile}/10 | bytes={packet.byte_size()} | "
f"fp={fp[:12]}..."
)
return recipients
def validate_outcome(self, agent_id: str, improved: bool) -> None:
"""
VOTE Election: reality validates synthesis utility.
If an institution applied a synthesized treatment insight and achieved
better patient outcomes, its vote_score rises.
"""
delta = 0.15 if improved else -0.08
self.agents[agent_id]["vote_score"] = round(
max(0.0, min(1.0, self.agents[agent_id]["vote_score"] + delta)), 3
)
outcome_str = "IMPROVED" if improved else "NO_IMPROVEMENT"
print(f"[VOTE] {agent_id} | outcome={outcome_str} | vote_score={self.agents[agent_id]['vote_score']}")
def synthesize(self, agent_id: str, phenotype_domain: str) -> Optional[dict]:
"""
Local synthesis: query accumulated outcome packets for the best-validated
intervention for a given phenotype domain.
No remote call. No raw genotype pull. Synthesis is local.
"""
profile = self.agents[agent_id]
relevant = [
p for p in profile["received_packets"]
if p["phenotype_domain"] == phenotype_domain
]
if not relevant:
return None
# Weight by outcome quality decile and similarity score
best = max(relevant, key=lambda p: p["outcome_quality_decile"] * p["similarity_score"])
# COMPETE Election: synthesis rank rises with successful local application
profile["compete_rank"] = round(min(2.0, profile["compete_rank"] + 0.05), 3)
result = {
"gene": best["gene_symbol"],
"recommended_intervention": best["intervention_category"],
"expected_outcome_direction": best["outcome_direction"],
"expected_quality_decile": best["outcome_quality_decile"],
"based_on_n_packets": len(relevant),
"synthesis_source": "local — no raw genotype data received",
}
print(
f"[SYNTHESIZE] {agent_id} | domain={phenotype_domain} | "
f"gene={best['gene_symbol']} | recommend={best['intervention_category']} | "
f"direction={best['outcome_direction']} | quality={best['outcome_quality_decile']}/10 | "
f"n_packets={len(relevant)}"
)
return result
def run_simulation(self) -> None:
"""
Simulate outcome packet emission, routing, and synthesis across
a network of genomic research institutions.
N agents → N(N-1)/2 unique synthesis opportunities (Θ(N²)).
Each agent pays O(log N) routing cost.
"""
N = len(self.agents)
synthesis_paths = N * (N - 1) // 2
routing_cost_per_agent = math.ceil(math.log2(N)) if N > 1 else 1
print(f"\n{'='*70}")
print(f"QIS GENOMICS NETWORK SIMULATION")
print(f"Registered institutions: {N}")
print(f"Synthesis paths available: N×(N-1)/2 = {synthesis_paths:,}")
print(f"Routing cost per agent: O(log {N}) ≈ {routing_cost_per_agent} hops")
print(f"{'='*70}\n")
# Outcome packets — validated deltas, zero raw genotype data
packets = [
(
"stanford_cancer_genomics",
GenomicsOutcomePacket(
gene_symbol="BRCA2",
variant_class="missense",
phenotype_domain="breast_cancer_treatment",
intervention_category="chemotherapy_parp_inhibitor",
outcome_type="progression_free_survival",
outcome_direction="benefit",
outcome_quality_decile=9,
cohort_size_tier="n101_500",
ancestry_group="EUR",
p_value_bin="genome_wide_sig",
institution_type="academic_medical_center",
),
),
(
"lagos_university_teaching_hospital",
GenomicsOutcomePacket(
gene_symbol="BRCA2",
variant_class="missense",
phenotype_domain="breast_cancer_treatment",
intervention_category="chemotherapy_parp_inhibitor",
outcome_type="progression_free_survival",
outcome_direction="benefit",
outcome_quality_decile=7,
cohort_size_tier="n21_100",
ancestry_group="AFR",
p_value_bin="suggestive",
institution_type="academic_medical_center",
),
),
(
"boston_childrens_rare_disease",
GenomicsOutcomePacket(
gene_symbol="CFTR",
variant_class="splicing",
phenotype_domain="cftr_lung_function",
intervention_category="small_molecule_modulator",
outcome_type="lung_function_fev1",
outcome_direction="benefit",
outcome_quality_decile=8,
cohort_size_tier="n6_20",
ancestry_group="EUR",
p_value_bin="suggestive",
institution_type="academic_medical_center",
),
),
(
"nairobi_rare_genetics_unit",
GenomicsOutcomePacket(
gene_symbol="HBB",
variant_class="missense",
phenotype_domain="sickle_cell_treatment",
intervention_category="hydroxyurea_gene_therapy",
outcome_type="hemoglobin_s_fraction",
outcome_direction="benefit",
outcome_quality_decile=8,
cohort_size_tier="n21_100",
ancestry_group="AFR",
p_value_bin="genome_wide_sig",
institution_type="lmic_clinic",
),
),
]
print("── PHASE 1: OUTCOME PACKET EMISSION AND ROUTING ──\n")
for emitter_id, packet in packets:
recipients = self.route(packet, emitter_id)
print(f" Delivered to: {recipients}\n")
print("── PHASE 2: VOTE ELECTION (REALITY VALIDATION) ──\n")
self.validate_outcome("oxford_oncogenomics", improved=True)
self.validate_outcome("mayo_clinic_pharmacogenomics", improved=True)
self.validate_outcome("amsterdam_umc_genetics", improved=False)
print("\n── PHASE 3: LOCAL SYNTHESIS QUERIES ──\n")
self.synthesize("oxford_oncogenomics", "breast_cancer_treatment")
self.synthesize("mayo_clinic_pharmacogenomics", "breast_cancer_treatment")
self.synthesize("cape_town_genomics_centre", "sickle_cell_treatment")
self.synthesize("toronto_sick_kids_rare", "cftr_lung_function")
print(f"\n{'='*70}")
print("COMPETE ELECTION RANKINGS (compete_rank):")
ranked = sorted(
self.agents.items(),
key=lambda x: x[1]["compete_rank"],
reverse=True
)
for agent_id, profile in ranked:
print(
f" {agent_id:<40} curate={profile['curate_weight']:.3f} | "
f"vote={profile['vote_score']:.3f} | compete={profile['compete_rank']:.3f}"
)
print(f"{'='*70}\n")
# ── Run ───────────────────────────────────────────────────────────────────────
if __name__ == "__main__":
router = GenomicsOutcomeRouter(similarity_threshold=0.40)
# Register institutions across types, ancestry focuses, and specializations
router.register_agent("stanford_cancer_genomics", ["breast_cancer_treatment", "ovarian_cancer_treatment"], ["EUR", "EAS"], "academic_medical_center")
router.register_agent("oxford_oncogenomics", ["breast_cancer_treatment", "colorectal_cancer_treatment"], ["EUR"], "academic_medical_center")
router.register_agent("mayo_clinic_pharmacogenomics", ["breast_cancer_treatment", "drug_metabolism"], ["EUR", "MIXED"], "academic_medical_center")
router.register_agent("lagos_university_teaching_hospital", ["breast_cancer_treatment", "sickle_cell_treatment"], ["AFR"], "academic_medical_center", rare_disease_focus=False)
router.register_agent("boston_childrens_rare_disease", ["cftr_lung_function", "rare_metabolic"], ["EUR"], "academic_medical_center", rare_disease_focus=True)
router.register_agent("toronto_sick_kids_rare", ["cftr_lung_function", "rare_metabolic", "mitochondrial_disease"], ["EUR", "MIXED"], "academic_medical_center", rare_disease_focus=True)
router.register_agent("amsterdam_umc_genetics", ["breast_cancer_treatment", "hereditary_cancer"], ["EUR"], "research_institute")
router.register_agent("nairobi_rare_genetics_unit", ["sickle_cell_treatment", "malaria_susceptibility"], ["AFR"], "lmic_clinic", rare_disease_focus=True)
router.register_agent("cape_town_genomics_centre", ["sickle_cell_treatment", "tb_susceptibility", "hiv_pharmacogenomics"], ["AFR"], "research_institute", rare_disease_focus=False)
router.register_agent("singapore_genome_institute", ["asian_pharmacogenomics", "breast_cancer_treatment"], ["EAS", "SAS"], "research_institute")
router.run_simulation()
Running this simulation with 10 registered institutions produces 10×9/2 = 45 unique synthesis paths. The Stanford BRCA2 missense outcome packet — genome-wide significant, EUR ancestry, n=101–500 cohort — routes immediately to Oxford Oncogenomics, Mayo Clinic Pharmacogenomics, and Amsterdam UMC Genetics: all institutions with breast cancer treatment in their phenotype domain and European ancestry focus. It does not route to the Singapore Genome Institute (EAS ancestry mismatch reduces similarity below threshold) until their ancestry profile overlaps on the relevant phenotype.
The Lagos University outcome packet — the same BRCA2 missense variant in an AFR ancestry cohort at n=21–100 with suggestive significance — routes to Cape Town Genomics Centre and Nairobi Rare Genetics Unit. The AFR ancestry match elevates routing priority for institutions focused on African population genomics. Stanford does not receive this packet at threshold — not because African ancestry data is less valuable, but because the EUR-focused breast cancer programs would weight it below their similarity threshold until they explicitly configure African ancestry relevance. The architecture respects ancestry-specific routing as a precision tool, not a hierarchy.
The Boston Children's Hospital CFTR splicing packet — n=6–20, suggestive significance, rare disease institution — routes to Toronto SickKids. A cohort of 14 CFTR splicing variant patients would never achieve genome-wide significance alone. In the QIS network, that packet's contribution is weighted by its outcome quality decile (8 — short time to functional improvement, validated response) rather than its cohort size. Toronto's synthesis layer receives it and can weight it accordingly. Two institutions with 6–20 patients each, synthesizing in real time, effectively combine their observations within the first treatment cycle.
The GWAS Replication Problem
The GWAS replication problem is, in part, an architecture problem.
A landmark GWAS finding — a variant achieving genome-wide significance at p<5×10⁻⁸ in a discovery cohort — often fails to replicate in independent cohorts. The reasons are multiple: winner's curse (first-observed effect sizes are inflated), population stratification (EUR-heavy discovery cohorts underpower replication in non-EUR ancestries), and cohort heterogeneity (phenotype definition inconsistencies between institutions).
The synthesis mechanism QIS provides addresses a specific subset of the replication problem: the failure of validated variant-outcome deltas to route between institutions in real time. A variant that fails to replicate at genome-wide significance in a second cohort may still be accumulating positive treatment outcome signals in the clinical institutions treating patients with that variant. Those clinical signals — pharmacogenomic responses, treatment outcomes, biomarker changes — are being generated continuously. They are not routing.
Visscher et al. (2017, American Journal of Human Genetics) documented that GWAS power grows with cohort size in a well-characterized curve. The curve shows that adding institutions — even small ones — compounds statistical power non-linearly in the region below genome-wide significance. The architecture that routes validated outcome packets from those small institutions, continuously, without requiring them to achieve local significance before contributing, is the mechanism that closes the gap between clinical observation and statistical validation.
The Global Equity Problem in Precision Medicine
Precision medicine's results are not globally distributed. The GWAS Catalog documented in 2019 (Sirugo, Williams, and Tishkoff, Cell, 2019) that 78% of GWAS participants were of European ancestry, while Europeans represent 16% of the global population. African, Indigenous, and other historically underrepresented populations are underserved by precision medicine findings derived overwhelmingly from EUR cohorts.
The cause is partially architectural. Institutions in the Global South cannot easily contribute to large centralized consortia. Data sharing agreements, data transfer costs, IRB requirements calibrated to high-income country research infrastructure, and consortium membership requirements all create barriers to participation that are independent of the scientific value of the clinical observations being made.
QIS outcome packets dissolve the participation barrier at the architectural level. A genomic research unit in Lagos or Nairobi does not need to join a consortium, negotiate a data sharing agreement, install a federated learning coordinator, or transmit raw sequencing data to a central aggregator. It needs to be able to emit a 512-byte outcome packet to the DHT network.
The Nairobi Rare Genetics Unit in the simulation above participates at identical architectural standing to Stanford Cancer Genomics. Its HBB missense sickle cell packet — validated in an AFR ancestry cohort, genome-wide significant — routes to Cape Town Genomics Centre and Lagos University Teaching Hospital because they share phenotype domain, ancestry group, and institution profile. The architecture does not weight the Nairobi packet less because of the institution's geographic location or resource level. It routes by semantic similarity.
The pharmacogenomics research produced by LMIC institutions — who treat the world's majority of disease burden — routes into the global synthesis network on the same terms as high-income country research. This is not a policy aspiration. It is a mathematical consequence of the routing design.
Three Elections in Genomics
CURATE is the selection force that elevates expertise. In a genomic network, an institution that consistently emits high-quality outcome packets — high outcome_quality_decile, genome-wide or near-genome-wide significance, outcomes validated across multiple patient encounters — accumulates an elevated routing weight. Its BRCA2 treatment outcome packets are prioritized in DHT routing. Other institutions do not vote to elevate it. The architecture observes output quality and adjusts routing priority accordingly. The institutions with the strongest clinical genomics programs develop larger routing footprints.
VOTE is the selection force that lets reality validate. In the simulation above, Oxford Oncogenomics received a synthesized intervention recommendation, applied it to a patient cohort with the corresponding variant-phenotype profile, and reported improved outcomes. That validation increments Oxford's vote_score. Across the network, institutions that consistently apply synthesized knowledge and report improved patient outcomes accumulate trust. The validator is patient outcome data, not a peer review panel.
COMPETE is the selection force that operates at network level. A sub-network of institutions synthesizing effectively — routing high-quality packets, applying validated interventions, reporting improved outcomes — develops higher compete_rank scores. A sub-network that stagnates loses routing priority. A regional precision oncology consortium that synthesizes treatment outcomes in real time develops more routing density than a geographically dispersed set of institutions with no common phenotype focus.
These are not governance mechanisms. They are feedback loops — the same selection pressures that cause scientific knowledge to accumulate in productive research communities and stagnate in isolated ones. The Three Elections are metaphors for natural selection forces. The architecture makes them computable.
Comparison: QIS Outcome Routing vs. Existing Genomic Synthesis Approaches
| Dimension | QIS Outcome Routing | GWAS Consortia | GA4GH Federated Query | Federated Learning for Genomics |
|---|---|---|---|---|
| Raw genomic data exposure | None — validated outcome packet only | None — summary statistics shared; negotiated process | None — presence/absence query only | Potential gradient leakage; central aggregator is a high-value target |
| Rare disease participation | N=1 and N=3 institutions emit valid packets | Rare variants excluded below consortium significance threshold | Beacon confirms variant presence but does not synthesize outcomes | N=1 institutions cannot compute meaningful local gradients |
| LMIC inclusion | Any institution that can emit a 512-byte packet participates at full architectural standing | Consortium membership requires infrastructure alignment | Beacon API deployment requires technical capacity | Requires local compute for gradient computation — scales poorly with institution resource level |
| Real-time response | Sub-minute routing on validated outcome | Months to years from study design to publication | Presence/absence query in near-real-time; no outcome synthesis | Round-based — one synthesis cycle per training epoch |
| Ancestry breadth | AFR, EAS, SAS, LMIC institutions route at identical architectural standing | EUR cohort bias is structural; non-EUR underrepresentation documented in GWAS Catalog | Query layer is ancestry-neutral; no outcome synthesis | Requires sufficient local cohort per ancestry group for gradient stability |
| Synthesis velocity | N(N-1)/2 paths at O(log N) routing cost | Linear in number of investigators who join the consortium | Presence/absence only — no outcome synthesis | Linear in number of FL rounds completed |
The Architecture Constraint
Every institution studying BRCA2 missense treatment outcomes is generating validated observations independently. The pharmacogenomic response pattern that a Lagos cohort validated in AFR ancestry patients is solved again, from zero prior knowledge, by every EUR-ancestry-focused institution that has not yet studied the AFR population — and by every AFR institution that cannot access the EUR results because they were published in a consortium dataset requiring institutional membership.
Every rare disease institution treating CFTR splicing variants is compounding clinical observations that will never, individually, reach genome-wide significance. The collective signal that could guide treatment decisions for rare disease patients globally is distributed across dozens of institutions with cohort sizes measured in single digits.
This is not a scientific constraint. The genetics are understood. The sequencing technology is mature. The treatment interventions exist. The observations are being made.
It is an architecture constraint. The architecture does not synthesize across institutions. Each institution is a node that generates genomic intelligence and loses it.
Architecture constraints yield to better architecture.
Citations
- Buniello, A. et al. "The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019." Nucleic Acids Research, 47(D1), D1005–D1012, 2019. https://doi.org/10.1093/nar/gky1120
- Gymrek, M. et al. "Identifying personal genomes by surname inference." Science, 339(6117), 321–324, 2013. https://doi.org/10.1126/science.1229566
- Sirugo, G., Williams, S.M., and Tishkoff, S.A. "The missing diversity in human genetic studies." Cell, 177(1), 26–31, 2019. https://doi.org/10.1016/j.cell.2019.02.048
- Cho, H. et al. "Secure, privacy-preserving and federated machine learning in medical imaging." Cell Systems, 14(7), 560–577, 2022. https://doi.org/10.1016/j.cels.2022.05.007
- Visscher, P.M. et al. "10 Years of GWAS Discovery: Biology, Function, and Translation." American Journal of Human Genetics, 101(1), 5–22, 2017. https://doi.org/10.1016/j.ajhg.2017.06.005
- National Organization for Rare Disorders (NORD). Rare Disease Facts. NORD, 2024. https://rarediseases.org/rare-disease-information/rare-disease-information/
- Global Alliance for Genomics and Health (GA4GH). Framework for Responsible Sharing of Genomic and Health-Related Data. GA4GH, 2021. https://www.ga4gh.org/
- Sweeney, L. et al. "Identifying participants in the Personal Genome Project by name." Journal of Privacy and Confidentiality, 2013. https://dataprivacylab.org/projects/pgp/
QIS was discovered by Christopher Thomas Trevethan. The architecture is protected under 39 provisional patents.
Part of the "Understanding QIS" series. Previous: Part 35 — QIS for Water Systems
Top comments (0)